Medicana Health Group has launched a new HPV vaccination and cervical cancer awareness campaign as part of a broader effort to strengthen preventive healthcare and improve public understanding of cervical cancer risk.
The campaign, introduced during World Immunisation Week 2026, focuses on HPV vaccination, regular medical check-ups and early diagnosis. Medicana says the initiative is part of its long-term prevention strategy and aims to support 25,000 vaccinations annually.
Human papillomavirus, known as HPV, is one of the most common viral infections of the reproductive tract. Persistent infection with high-risk types of HPV is linked to nearly all cases of cervical cancer. While cervical cancer remains a major global health issue, it is also considered one of the most preventable forms of cancer when vaccination, screening and timely treatment are brought together.
Medicana’s campaign places particular emphasis on the full prevention pathway, rather than vaccination alone. The group is encouraging individuals to consider regular check-ups and physician-recommended screenings as part of a wider approach to women’s health.
Through its check-up packages, Medicana offers access to relevant examinations, including gynaecological evaluation and further tests where considered appropriate by physicians. The aim is to help people take earlier, more informed steps in protecting their long-term health.
As part of the campaign, Medicana also organised a scientific event titled “The Role of HPV Vaccination in the Prevention of Cervical Cancers”. The conference opened with remarks by Prof. Dr Tezer Kutluk and included a presentation by Prof. Dr Ahmet Göçmen, Gynaecology and Obstetrics Specialist at Medicana Ataşehir Hospital.
The session explored the link between HPV and cervical cancer, the protective role of vaccination and the importance of informed public dialogue. It concluded with a question-and-answer session, allowing participants to engage directly with medical experts.
“Cervical cancer remains a significant global public health challenge, despite being largely preventable with the tools available today. At the heart of this issue lies the underuse of effective prevention and early detection strategies. The HPV vaccine is the most powerful protective measure in this process,” said Associate Professor Dr Eylem Alıcı, Africa Regional Director of Medicana Health Group.
“Our approach is to build a comprehensive healthcare journey that extends from vaccination and screening to early diagnosis and treatment. Our goal is not only to treat the disease, but also to foster a sustainable culture of health awareness that helps prevent it from developing in the first place.”
The campaign is also aligned with the World Health Organisation’s global cervical cancer elimination strategy, which calls for countries to reach 90 percent HPV vaccination coverage, 70 percent screening coverage and 90 percent access to treatment for women identified with cervical disease by 2030.
By connecting vaccination awareness with regular controls and early diagnosis, Medicana is positioning the campaign as part of a wider public health conversation around prevention, women’s health and continuity of care.
Founded in 1992, Medicana Health Group is one of Türkiye’s leading privately owned healthcare providers. The group operates 19 hospitals across Türkiye, the United Kingdom and Bosnia and Herzegovina, serving more than five million patients each year, including a large international patient base.
